Le Lézard
Classified in: Health
Subjects: PDT, CPG, CMG, CFG

The Mental Health Commission of Canada and Ontario Shores Centre for Mental Health Sciences launch a national demonstration project to advance schizophrenia treatment and care delivery in Canada


OTTAWA, ON, Jan. 23, 2024 /CNW/ - The Mental Health Commission of Canada (MHCC) and Ontario Shores Centre for Mental Health Sciences (Ontario Shores) are collaborating on a nationwide demonstration project to advance treatment, strengthen care delivery, and improve outcomes for those living with schizophrenia. Over 18 months, participating health-care sites will receive customized resources and support to expand the implementation of Ontario Health's (OH) Schizophrenia Quality Standards (Standards).

The MHCC and Ontario Shores are pleased to welcome the following demonstration sites to the project:

These sites will receive tools, education, and training to implement the Standards based on specific regional, cultural, and organizational needs.

The Standards were developed by Ontario Health and informed by guidance from the National Institute for Health and Care Excellence (NICE). Adapted to the Canadian context and local conditions, the Standards include a series of 11 statements for Schizophrenia Care for Adults in Hospitals and 15 statements for Schizophrenia Care in the Community for Adults.

Quotes

"This project provides an opportunity to ensure equitable access to the highest standards of care for people living with schizophrenia in Canada. The Mental Health Commission of Canada is pleased to work with our partners on this milestone. The co-creation of a national toolkit to expand these Quality Standards across the country will reduce the variability in care for people living with schizophrenia."

Michel Rodrigue, President and CEO
Mental Health Commission of Canada

"Ontario Shores is delighted to share our expertise in Quality Standard implementation with four new partners from across the country and to partner with the Mental Health Commission of Canada to do so. This project will ensure that people receiving treatment for schizophrenia at our partner sites will receive the highest quality care possible. Together with the MHCC, we aim to accelerate the delivery of the most strongly evidence-based care and to elevate measurement-based care to improve patient outcomes."

Karim Mamdani, President and CEO
Ontario Shores Centre for Mental Health Sciences

About MHCC

The MHCC leads the development and dissemination of innovative programs and tools to support the mental health and wellness of Canadians. Through its unique mandate from the Government of Canada, the MHCC supports federal, provincial, and territorial governments as well as organizations in the implementation of sound public policy. The MHCC's current mandate aims to deliver on priority areas identified in the Mental Health Strategy for Canada in alignment with the delivery of its strategic plan

About Ontario Shores

Ontario Shores Centre for Mental Health Sciences (Ontario Shores) is a leader in mental health care, providing a range of specialized assessment and treatment services for people living with complex mental illness. Patients benefit from a recovery-oriented environment of care, built on compassion, inspiration, and hope. Ontario Shores engages in research, education, and advocacy initiatives to advance the mental health care system. 

SOURCE Mental Health Commission of Canada


These press releases may also interest you

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...



News published on and distributed by: